K
50
-3
EXPD
37
-2
PGR
59
5
MLM
41
-2
JNJ
36
3
UA
38
-9
DG
14
-3
PEG
55
2
AMG
54
-4
A
39
-2
AAL
59
-4
IR
55
-3
CA
25
-7
NUE
39
-4
GME
54
-3
BK
66
-2
MCHP
43
6
VMC
48
-2
JWN
61
5
O
19
-12
K
50
-3
EXPD
37
-2
PGR
59
5
MLM
41
-2
JNJ
36
3
UA
38
-9
DG
14
-3
PEG
55
2
AMG
54
-4
A
39
-2
AAL
59
-4
IR
55
-3
CA
25
-7
NUE
39
-4
GME
54
-3
BK
66
-2
MCHP
43
6
VMC
48
-2
JWN
61
5
O
19
-12
Financhill
Back

Climb Bio Quote, Financials, Valuation and Earnings

Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!

Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)
Sell
22

CLYM
Climb Bio

Last Price:
2.60
Seasonality Move:
11.17%

7 Day Trial

ALL ACCESS PASS

$ 7

The dark truth about AI

Click here to learn more...

Climb Bio Price Quote

$2.60

Climb Bio Key Stats

Sell
22
Climb Bio (CLYM) is a Sell
Day range:
$2.57 - $2.90
52-week range:
$2.52 - $11.55
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.8%
Volume:
137.3K
Avg. volume:
259.5K
1-year change:
0%
Market cap:
$174.8M
Revenue:
$0
EPS:
$-2.13

How Much Does Climb Bio Make?

Data Unavailable

Is Climb Bio Growing As A Company?

Data Unavailable

Climb Bio Stock Price Performance

  • Did Climb Bio Stock Go Up Last Month?
    Climb Bio share price went down by -26.35% last month
  • Did CLYM's Share Price Rise Over The Last Year?
    CLYM share price rose by 0% over the past 1 year

What Is Climb Bio 52-Week High & Low?

  • What Is Climb Bio’s 52-Week High Share Price?
    Climb Bio has traded as high as $11.55 over the past 52 weeks
  • What Is Climb Bio’s 52-Week Low Share Price?
    Climb Bio has traded as low as $2.52 over the past 52 weeks

Climb Bio Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Climb Bio?

  • How Much Debt Does Climb Bio Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Climb Bio Have?
    Cash and short term investments quarterly total is $193.4M
  • What Is Climb Bio’s Book Value Per Share?
    Book value per share is 3.25

Is Climb Bio Cash Flow Positive?

  • What Is CLYM Cash Flow From Operations?
    Cash flow from operations (TTM) is -$11M
  • What Is Climb Bio’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $131M
  • What Is Climb Bio’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$30.9M

Climb Bio Return On Invested Capital

Data Unavailable

Climb Bio Earnings Date & Stock Price

  • What Is Climb Bio's Stock Price Today?
    A single share of CLYM can be purchased today for 2.60
  • What Is Climb Bio’s Stock Symbol?
    Climb Bio trades on the nasdaq under the ticker symbol: CLYM
  • When Is Climb Bio’s Next Earnings Date?
    The next quarterly earnings date for Climb Bio is scheduled on May 15, 2025
  • When Is CLYM's next ex-dividend date?
    Climb Bio's next ex-dividend date is December 14, 2024
  • How To Buy Climb Bio Stock?
    You can buy Climb Bio shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Climb Bio Competitors

  • Who Are Climb Bio's Competitors?
    Below is a list of companies who compete with Climb Bio or are related in some way:
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Oragenics Inc (OGEN)
    • Palatin Technologies Inc (PTN)
    • Theriva Biologics Inc (TOVX)

Climb Bio Dividend Yield

  • What Is CLYM Dividend Yield?
    Climb Bio’s dividend yield currently is 0%
  • What Is Climb Bio’s Payout Ratio?
    Climb Bio’s payout ratio is 0%
  • When Did Climb Bio Last Pay A Dividend?
    The latest dividend pay date is December 14, 2024
  • What Is Climb Bio’s Dividend Per Share?
    Climb Bio pays a dividend of $0.00 per share

Climb Bio Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 10.00
Upside from Last Price: 284.62%

Major Shareholders

  • How many CLYM shares are owned by institutional investors?
    97.1M CLYM shares are owned by institutional investors
  • How many CLYM shares are owned by insiders?
    320.9K CLYM shares are owned by insiders